Itolizumab – a humanized anti-CD6 monoclonal antibody with better side effects profile for the treatment of psoriasis [Corrigendum]

Anti CD-6 Monoclonal Antibodies in the Management of Generalised Pustular Psoriasis

“…[ 11 13 14 15 ] There is a role of CD-6 in the pathogenesis of psoriasis, which is a surface glycoprotein found on the outer surface of mature T cells and immature B cells. [ 10 16 17 18 19 ] Its extracellular region has three scavenger receptor cysteine-rich (SRCR) domains (D). T and B lymphocytes and antigen presenting cells (APC) express activated leucocyte cell adhesion molecule (AL CAM), which is a ligand for CD 6.…”

“…T and B lymphocytes and antigen presenting cells (APC) express activated leucocyte cell adhesion molecule (AL CAM), which is a ligand for CD 6. [ 10 16 17 18 19 ] This ALCAM binds with the SRCR of CD-6, and thus helps in the interaction between T cells and APCs. [ 10 16 17 18 ] This immunological synapse leads to the differentiation, proliferation and maturation of T cells.…”

“…[ 10 16 17 18 19 ] This ALCAM binds with the SRCR of CD-6, and thus helps in the interaction between T cells and APCs. [ 10 16 17 18 ] This immunological synapse leads to the differentiation, proliferation and maturation of T cells. CD-6 also increases the release of TNF-α, interferon gamma (IFN-γ) and IL-6, which leads to keratinocyte activation and acanthosis, hyperkeratosis and parakeratosis histopathologically.…”

“…It is an upstream blocker which inhibits the co-stimulation of T cells, thereby decreasing the release of cytokines by Th1 and Th17 cells which have a very important role in the disease pathogenesis. [ 10 ] Itolizumab also does not cause any paradoxical exacerbation of GPP, like TNF antagonists. It is approved for use in psoriasis vulgaris in India, and we hereby share our experience of its use in three cases of GPP.…”

Insights into biological therapeutic strategies for COVID-19

“…A humanized IgG1 monoclonal antibody, Itolizumab (Alzumab, Biocon Ltd.), specifically binds to domain 1 of CD6 and downregulates the transcription of pro-inflammatory cytokine genes, thus leading to decreased levels of IFN-𝛾, IL-6, and TNF-𝛼, resulting in attenuation of cytokine storm and T cell infiltration. Itolizumab was initially developed for various cancers and was later approved in India in 2013 for treatment of moderate to severe chronic plaque psoriasis [120] . Considering its unique mechanism of action in ameliorating CRS, which is the leading cause of death in COVID-19, itolizumab has been repurposed for COVID-19.…”